Voyager Therapeutics, Inc. · NASDAQ:VYGR
Voyager Therapeutics — ASGCT 2026 Annual Meeting
17 slides from Voyager Therapeutics's conference presentation, May 15, 2026
Slide 1: Directed evolution of muscular and neuromuscular capsid variants in both mice and non-human primates
Directed evolution of muscular and neuromuscular capsid variants in both mice and non-human primates (#422) Tyler Moyer ASGCT 2026 Annual Meeting AAV Capsid Engineering IV Friday, May 15, 2026
Slide 2: Disclosure
Disclosure Tyler Moyer is a full-time employee of Voyager Therapeutics, Inc. 2 |
Slide 3: The TRACER Platform Delivers Groundbreaking AAV Capsids
The TRACERTM Platform Delivers Groundbreaking AAV Capsids • Voyager’s TRACER engineering platform focuses on evolving AAV capsids with tissue-specific targeting for maximal gene delivery and minimum off-target effect upon systemic delivery. • TRACER was first applied to deliver transformative, BBB-p
Slide 4: AAV Directed Evolution Platforms (TRACER) Can Be Used to Evolve Tissue-Specific AAV Variants
AAV Directed Evolution Platforms (TRACER) Can Be Used to Evolve Tissue-Specific AAV Variants • TRACER (Tropism Redirection of AAV by Cell-type specific Expression of RNA) evolution of peptide libraries Mouse Muscle Enrichment Rel. to AAV9 AAV Library 2 28 days In-life 1 Capsid Library Library mRNA 3
Slide 5: TRACER-Derived Muscle Capsids Demonstrate Superior Muscle Transduction Over AAV9 in Mice
TRACERTM-Derived Muscle Capsids Demonstrate Superior Muscle Transduction Over AAV9 in Mice AAV9 Benchmark Capsid 1 Capsid 2 Capsid 3 Capsid 4 Capsid 5 Dorsal View 1e10 Ventral View 5e7 Imaging 2 weeks post-dosing 6-8 week old female B6(cg)-Tyrc-2J/J mice IV-dosed with 2.5E13 VG/kg of capsid packaged
Slide 6: VCAP-290 Demonstrates Superior Muscle Transduction Over AAV9 in Mice
VCAP-290 Demonstrates Superior Muscle Transduction Over AAV9 in Mice Quadriceps Gastrocnemius Heart Diaphragm Quadriceps Heart Liver AAV9 Transgene expression rel. to AAV9 Transgene expression rel. to AAV9 150 20 1.5 Vector genomes rel. to AAV9 15 Benchmark 100 1.0 10 50 0.5 5 VCAP-290 0 0 0.0 VC hm
Slide 7: VCAP-290 Transduces 100% of Muscle Fibers at 5E12 VG/kg in Mice
VCAP-290 Transduces 100% of Muscle Fibers at 5E12 VG/kg in Mice AAV9 VCAP-290 AAV9 VCAP-290 Quadriceps Quadriceps Heart Heart 6-8 week old female B6(cg)-Tyrc-2J/J mice IV-dosed 6-8 week old female B6(cg)-Tyrc-2J/J mice IV-dosed with 2.5E13 VG/kg of capsid packaged with ssCAG- with 5.0E12 VG/kg of ca
Slide 8: VCAP-290 Demonstrates Superior Skeletal Muscle Transduction Over AAV9 in NHPs
VCAP-290 Demonstrates Superior Skeletal Muscle Transduction Over AAV9 in NHPs Quadriceps Transgene Expression 40 0.25 % DAB+ Nuclei 28.9 60 Rel. to AAV9 30 0.20 VG/DG 0.15 40 20 11.9 0.10 20 10 5.9 0.05 0 0.00 0 V9 ark 290 ch V9 A rk 0 ch V9 A k 90 A A hm P- 29 VC ma VC ar B AA P2 P- B AA A m c en V
Slide 9: VCAP-290 Demonstrates Superior Cardiac Muscle Transduction Over AAV9 in NHPs
VCAP-290 Demonstrates Superior Cardiac Muscle Transduction Over AAV9 in NHPs Heart Transgene Expression 30 0.8 25 20.4 %DAB+ Nuclei Rel. to AAV9 20 0.6 VG/DG 20 15 9.4 0.4 6.3 10 10 0.2 5 0 0.0 0 V9 ark 290 ch 9 A rk 0 ch 9 A rk 0 A A hm P- en AV 29 en AV 29 VC ma VC ma P- c A P- A A AAV9-CBA-cH2B-T
Slide 10: Continuous Directed Evolution of VCAP-290 Allows Selection of 2nd Generation Capsids
Continuous Directed Evolution of VCAP-290 Allows for Selection of 2nd Generation Capsids with Improved Peripheral Tissue Detargeting 1.5 C-DRG 2.5 Liver Transgene Expression 2.0 Rel. to AAV9 1.0 1.5 1.0 2nd Generation TRACER Evolution Enrichment in NHP Liver Relative to VCAP-290 0.5 0.5 Nterm Cterm
Slide 11: Evolution of Multi-Tropic AAV Capsids for Neuromuscular Indications
Evolution of Multi-Tropic AAV Capsids for Neuromuscular Indications CNS tropism Muscle/heart tropism Neuromuscular VCAP-Gen2 VCAP-290 VCAP-336 VCAP-337 11 |
Slide 12: Neuromuscular Capsid VCAP-336 Demonstrates Dual Tropism to Muscle and the CNS in Mice
Neuromuscular Capsid VCAP-336 Demonstrates Dual Tropism to Muscle and the CNS in Mice Benchmark VCAP-Gen2 VCAP-336 (muscular) (CNS-tropic) (neuromuscular) Transgene Expression Transgene Expression Transgene Expression 15 Rel. to AAV9 10 Skeletal Muscle 5 0 Liver Transgene Expression 15 2.0 Rel. to A
Slide 13: Neuromuscular Capsid VCAP-337 Retains Tropism to Muscle in NHPs
Neuromuscular Capsid VCAP-337 Retains Tropism to Muscle in NHPs AAV9-CBA-cH2B-Tag1 Benchmark-CBA-cH2B-Tag2 AAV9 Benchmark VCAP-337 VCAP-337-CBA-cH2B-Tag4 n=3Cynomolgus Quadriceps macaques Each capsid IV-dosed at 4E12 vg/kg Quadriceps Heart 50 40 15 Transgene Expression Transgene Expression Heart 27.
Slide 14: Neuromuscular Capsid VCAP-337 Demonstrates Higher CNS Tropism than VCAP-Gen2
Neuromuscular Capsid VCAP-337 Demonstrates Higher CNS Tropism than VCAP-Gen2 Motor Cortex AAV9-CBA-cH2B-Tag1 Benchmark-CBA-cH2B-Tag2 AAV9 VCAP-337 VCAP-Gen2* n=3Cynomolgus Pre-Analysis VCAP-337-CBA-cH2B-Tag4 macaques Each capsid IV-dosed at 4E12 vg/kg Liver Rel. to AAV9 in Motor Cortex 400 Transgene
Slide 15: Summary
Summary • VCAP-290 demonstrates strong tropism to skeletal and cardiac muscles in both mice and non- human primates compared to AAV9. • ~100X over AAV9 in mouse skeletal muscle • ~10X over AAV9 in mouse cardiac muscle • ~25X over AAV9 in NHP skeletal muscle • ~13X over AAV9 in NHP cardiac muscle • V
Slide 16: Acknowledgements
Acknowledgements Capsid Discovery Vector Production Tyler Moyer Jack Studer Neuroscience Mathieu Nonnenmacher Jordan Routhier Roberto Calitri Richard Lu Tim Fiore Cassie Retzlaff Damien Maura Ruohong Zhou Meg Dalrymple Renuk Lakshmanan Dhiral Shah Maneesha Paranjpe Tania Lemos Charlotte Chung Matt C
Slide 17: Questions?
Questions? voyager